30 closest matches · ranked by relevance
Advanced Cancer
Primary: Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level — 1; 3; 0; 2 Participants
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Metastatic Carcinoma
Primary: Number of Participants With SABR Successfully Delivered in One Fraction — 30 Participants
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Progressive Metastatic Malignancies
Primary: The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies — 0; 2; 4 Events
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Advanced Solid Tumor
Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Lung Cancer · Mesothelioma
Primary: Disease Control Rate at 4 Months — 8 Participants
Solid Tumor, Adult
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0; 0; 0 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 0; 3 Number of participants
Solid Tumors
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) Determined in Part-A — 0; 0; 0; 0 subjects